(Reuters) -The U.S. health regulator has changed its strain recommendation for the 2024-25 COVID-19 vaccines, as it asked manufacturers to update the new shots to target the KP.2 variant, if feasible, instead of the JN.1 lineage it sought to target earlier. The Food and Drug Administration’s change in recommendation, in an update dated Thursday, comes […]
The Food and Drug Administration said Thursday it had advised drugmakers to update the Covid vaccines to target the KP.2 strain, a descendant of the highly contagious JN.1 variant that began circulating widely in the U.S. this winter. The announcement came just over a week after an FDA advisory panel voted unanimously to recommend that […]
(Reuters) -Vaccine makers should consider targeting one of the currently dominant JN.1 variants and JN.1-derived subvariants such as KP.2 as they develop COVID-19 shots for the 2024-2025 campaign, the U.S. Food and Drug Administration’s staff said on Monday. The FDA reviewers said since the difference between JN.1 and newer subvariants such as KP.2 subvariants is […]
For the last few months, JN.1 has been the dominant COVID-19 variant in the United States, making up the majority of cases. A new variant, however, has taken over and may lead to an increase in cases this summer. KP.2, which is an offshoot of the omicron variant, currently accounts for an estimated 28.2% of […]